| 1 | for drug delivery shows | | | | | | | 5 | 0.54% |
| 2 | marchesan – 2021 – | | | | | | | 5 | 0.54% |
| 3 | promise in pediatric dentistry | | | | | | | 4 | 0.44% |
| 4 | news october 10 2021 | | | | | | | 4 | 0.44% |
| 5 | 2021 – journal of | | | | | | | 4 | 0.44% |
| 6 | – 2021 – journal | | | | | | | 4 | 0.44% |
| 7 | history of covid‐19 primary | | | | | | | 4 | 0.44% |
| 8 | implantology orthodontics periodontology predental | | | | | | | 4 | 0.44% |
| 9 | – marchesan – 2021 | | | | | | | 4 | 0.44% |
| 10 | drug delivery shows promise | | | | | | | 4 | 0.44% |
| 11 | delivery shows promise in | | | | | | | 4 | 0.44% |
| 12 | infection salivary transmission and | | | | | | | 4 | 0.44% |
| 13 | shows promise in pediatric | | | | | | | 3 | 0.33% |
| 14 | endodontics and us endo | | | | | | | 3 | 0.33% |
| 15 | to support access to | | | | | | | 3 | 0.33% |
| 16 | program to support access | | | | | | | 3 | 0.33% |
| 17 | 68 number 7university of | | | | | | | 3 | 0.33% |
| 18 | number 7university of pennsylvania | | | | | | | 3 | 0.33% |
| 19 | 7university of pennsylvania almanac | | | | | | | 3 | 0.33% |
| 20 | and us endo partners | | | | | | | 3 | 0.33% |
| 21 | to vie for miss | | | | | | | 3 | 0.33% |
| 22 | nampa teacher to vie | | | | | | | 3 | 0.33% |
| 23 | teacher to vie for | | | | | | | 3 | 0.33% |
| 24 | volume 68 number 7university | | | | | | | 3 | 0.33% |
| 25 | prosthodontics gdch to have | | | | | | | 3 | 0.33% |
| 26 | gdch to have centre | | | | | | | 3 | 0.33% |
| 27 | to have centre of | | | | | | | 3 | 0.33% |
| 28 | have centre of superspeciality | | | | | | | 3 | 0.33% |
| 29 | dentistry use of polysaccharides | | | | | | | 3 | 0.33% |
| 30 | use of polysaccharides as | | | | | | | 3 | 0.33% |
| 31 | of polysaccharides as carriers | | | | | | | 3 | 0.33% |
| 32 | as carriers for drug | | | | | | | 3 | 0.33% |
| 33 | carriers for drug delivery | | | | | | | 3 | 0.33% |
| 34 | news october 11 2021 | | | | | | | 3 | 0.33% |
| 35 | in pediatric dentistry study | | | | | | | 3 | 0.33% |
| 36 | post‐acute implications – marchesan | | | | | | | 3 | 0.33% |
| 37 | implications – marchesan – | | | | | | | 3 | 0.33% |
| 38 | transmission and post‐acute implications | | | | | | | 3 | 0.33% |
| 39 | allen smith pachall and | | | | | | | 3 | 0.33% |
| 40 | exhibit at leading orthodontist | | | | | | | 3 | 0.33% |